The Parliamentary Standing Committee on Health has come down heavily on the Department of Ayush for going slow in revising and implementing the centrally sponsored scheme for improving the quality of Ayurveda, Siddha, Unani and Homoeopathic (ASU&H) drugs.
“The Committee is not happy with the snail’s pace of the progress made in the matter. It is already the second year of the 12th Plan and if the Department is still in the process of revising the Centrally Sponsored Scheme for supporting State Drug Testing Laboratories and Pharmacies, it is a sad commentary on its decision making process,” the recent report of the panel said.
“The Committee is at a loss to understand as to how the requirements of quality control will be met if the revision of the Scheme is delayed inordinately. The Committee, therefore, recommends to quickly finalize Scheme and implement the same,” it said.
The panel had in its earlier report recommended revision of the quality control scheme at the earliest. “The Committee observes that there is a separate chapter IV A in the Drugs and Cosmetics Act 1940 which regulates the manufacture and sale of ASU&H drugs. Since the enforcement of provisions of Drugs and Cosmetics Act and Rules made there under is under the purview of State Drug Licensing and Drug Control Authorities, the state drugs regulatory framework has a crucial role to play in ensuring safety and quality of ASU&H drugs. It is in this context that strengthening of State Drug Testing Laboratories which are facing infrastructure constraints, and shortage of manpower, assume added significance,” its earlier report had said.
Detailing the actions taken on the recommendations, the Department said an evaluation was made on the scheme by an outside agency and the report was received. “The Department has initiated action to revise the scheme with enhanced scope and suitable modification of funding pattern in the 12th Plan. It is intended to make the scheme broadbased for covering priority requirements of quality control of ASU&H drugs including improvement of infrastructural and functional capacities of State Drug Testing Laboratories,” the department said.
Source : PharmaBiz